Bay, Benjamin
Blaum, Christopher
Kellner, Caroline
Bei der Kellen, Ramona
Ojeda, Francisco
Waibel, Julia
Arnold, Natalie
Behrendt, Christian-A.
Rimmele, David L.
Thomalla, Goetz
Twerenbold, Raphael
Blankenberg, Stefan
Zyriax, Birgit
Brunner, Fabian J.
Waldeyer, Christoph
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 10 September 2023
Accepted: 28 November 2023
First Online: 8 December 2023
Change Date: 8 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-51444-6
Competing interests
: GT reports honoraria as consultant or lecturer from Acandis, Alexion, Amarin, Bayer, Boehringer Ingelheim, BristolMyersSquibb/Pfizer, Daiichi Sankyo and Stryker, all outside of the submitted work. RT reports research support from the German Center for Cardiovascular Research (DZHK), the Kühne Foundation, the Joachim Herz Foundation as well as speaker honoraria/consulting honoraria from Abbott, Amgen, Astra Zeneca, Psyros, Roche, Siemens, Singulex and Thermo Scientific BRAHMS. RT is co-founder and shareholder of the ART-EMIS Hamburg GmbH, which holds an international patent application on the use of a computing device to estimate the probability of myocardial infarction (International Publication Numbers WO2022043229A1, TW202219980A). SB has received research funding from Abbott Diagnostics, Bayer, SIEMENS, Singulex and Thermo Fisher. SB received honoraria for lectures from Abbott, Abbott Diagnostics, AstraZeneca, Bayer, AMGEN, Medtronic, Pfizer, Roche, SIEMENS Diagnostics, SIEMENS, Thermo Fisher and as member of Advisory Boards and for consulting for Bayer, Novartis and Thermo Fisher, all outside of the submitted work. FJB reports grants from Daiichi Sankyo, Pfizer, and Sanofi, non-financial support from Abbott, ASAHI INTECC, and Inari Medical, personal fees from Amgen and Novartis outside of the submitted work. CW reports lecture and consulting fees from AMGEN, Novartis, Daiichi Sankyo, Sanofi and AstraZeneca, all outside of the submitted work. All other authors declare no competing interests.